|
MechanismHIV-1 gag inhibitors |
|
|
Active Indication- |
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
治疗性重组腺病毒艾滋病gag疫苗(Ad5-HIVgag)I期临床研究
[Translation] Phase I clinical study of therapeutic recombinant adenovirus HIV gag vaccine (Ad5-HIVgag)
本研究是观察成年HIV感染者在接受HAART治疗的基础上,联合应用重组腺病毒艾滋病gag疫苗(Ad5-HIVgag)的耐受性和安全性,为后续的临床试验提供安全的给药方案;其次是初步了解疫苗的免疫原性。
[Translation] This study aims to observe the tolerance and safety of recombinant adenovirus AIDS gag vaccine (Ad5-HIVgag) in adult HIV-infected patients receiving HAART treatment, in order to provide a safe dosing regimen for subsequent clinical trials; secondly, to gain a preliminary understanding of the immunogenicity of the vaccine.
100 Clinical Results associated with National Institute for Viral Disease Control and Prevention, China CDC
0 Patents (Medical) associated with National Institute for Viral Disease Control and Prevention, China CDC
100 Deals associated with National Institute for Viral Disease Control and Prevention, China CDC
100 Translational Medicine associated with National Institute for Viral Disease Control and Prevention, China CDC